These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38245116)

  • 1. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial.
    Tricou V; Yu D; Reynales H; Biswal S; Saez-Llorens X; Sirivichayakul C; Lopez P; Borja-Tabora C; Bravo L; Kosalaraksa P; Vargas LM; Alera MT; Rivera L; Watanaveeradej V; Dietze R; Fernando L; Wickramasinghe VP; Moreira ED; Fernando AD; Gunasekera D; Luz K; Oliveira AL; Tuboi S; Escudero I; Hutagalung Y; Lloyd E; Rauscher M; Zent O; Folschweiller N; LeFevre I; Espinoza F; Wallace D
    Lancet Glob Health; 2024 Feb; 12(2):e257-e270. PubMed ID: 38245116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
    Biswal S; Borja-Tabora C; Martinez Vargas L; Velásquez H; Theresa Alera M; Sierra V; Johana Rodriguez-Arenales E; Yu D; Wickramasinghe VP; Duarte Moreira E; Fernando AD; Gunasekera D; Kosalaraksa P; Espinoza F; López-Medina E; Bravo L; Tuboi S; Hutagalung Y; Garbes P; Escudero I; Rauscher M; Bizjajeva S; LeFevre I; Borkowski A; Saez-Llorens X; Wallace D;
    Lancet; 2020 May; 395(10234):1423-1433. PubMed ID: 32197105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.
    Tricou V; Sáez-Llorens X; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Saldaña de Suman O; Montenegro N; DeAntonio R; Mazara S; Vargas M; Mendoza D; Rauscher M; Brose M; Lefevre I; Tuboi S; Borkowski A; Wallace D
    Lancet; 2020 May; 395(10234):1434-1443. PubMed ID: 32197107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Mazara S; Vargas M; Brose M; Rauscher M; Tuboi S; Borkowski A; Wallace D
    Lancet Infect Dis; 2018 Feb; 18(2):162-170. PubMed ID: 29122463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial.
    Walsh MR; Alam MS; Pierce KK; Carmolli M; Alam M; Dickson DM; Bak DM; Afreen S; Nazib F; Golam K; Qadri F; Diehl SA; Durbin AP; Whitehead SS; Haque R; Kirkpatrick BD
    Lancet Infect Dis; 2024 Feb; 24(2):150-160. PubMed ID: 37776876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents.
    Biswal S; Reynales H; Saez-Llorens X; Lopez P; Borja-Tabora C; Kosalaraksa P; Sirivichayakul C; Watanaveeradej V; Rivera L; Espinoza F; Fernando L; Dietze R; Luz K; Venâncio da Cunha R; Jimeno J; López-Medina E; Borkowski A; Brose M; Rauscher M; LeFevre I; Bizjajeva S; Bravo L; Wallace D;
    N Engl J Med; 2019 Nov; 381(21):2009-2019. PubMed ID: 31693803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial.
    Kallas EG; Precioso AR; Palacios R; Thomé B; Braga PE; Vanni T; Campos LMA; Ferrari L; Mondini G; da Graça Salomão M; da Silva A; Espinola HM; do Prado Santos J; Santos CLS; Timenetsky MDCST; Miraglia JL; Gallina NMF; Weiskopf D; Sette A; Goulart R; Salles RT; Maestri A; Sallum AME; Farhat SCL; Sakita NK; Ferreira JCOA; Silveira CGT; Costa PR; Raw I; Whitehead SS; Durbin AP; Kalil J
    Lancet Infect Dis; 2020 Jul; 20(7):839-850. PubMed ID: 32220283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of Butantan-DV in participants aged 2-59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil.
    Nogueira ML; Cintra MAT; Moreira JA; Patiño EG; Braga PE; Tenório JCV; de Oliveira Alves LB; Infante V; Silveira DHR; de Lacerda MVG; Pereira DB; da Fonseca AJ; Gurgel RQ; Coelho IC; Fontes CJF; Marques ETA; Romero GAS; Teixeira MM; Siqueira AM; Boaventura VS; Ramos F; Júnior EE; de Moraes JC; Whitehead SS; Esteves-Jaramillo A; Shekar T; Lee JJ; Macey J; Kelner SG; Coller BG; Boulos FC; Kallás EG;
    Lancet Infect Dis; 2024 Nov; 24(11):1234-1244. PubMed ID: 39116904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.
    Osorio JE; Velez ID; Thomson C; Lopez L; Jimenez A; Haller AA; Silengo S; Scott J; Boroughs KL; Stovall JL; Luy BE; Arguello J; Beatty ME; Santangelo J; Gordon GS; Huang CY; Stinchcomb DT
    Lancet Infect Dis; 2014 Sep; 14(9):830-8. PubMed ID: 25087476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
    Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
    Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.
    Capeding MR; Tran NH; Hadinegoro SR; Ismail HI; Chotpitayasunondh T; Chua MN; Luong CQ; Rusmil K; Wirawan DN; Nallusamy R; Pitisuttithum P; Thisyakorn U; Yoon IK; van der Vliet D; Langevin E; Laot T; Hutagalung Y; Frago C; Boaz M; Wartel TA; Tornieporth NG; Saville M; Bouckenooghe A;
    Lancet; 2014 Oct; 384(9951):1358-65. PubMed ID: 25018116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults.
    Kallás EG; Cintra MAT; Moreira JA; Patiño EG; Braga PE; Tenório JCV; Infante V; Palacios R; de Lacerda MVG; Batista Pereira D; da Fonseca AJ; Gurgel RQ; Coelho IC; Fontes CJF; Marques ETA; Romero GAS; Teixeira MM; Siqueira AM; Barral AMP; Boaventura VS; Ramos F; Elias Júnior E; Cassio de Moraes J; Covas DT; Kalil J; Precioso AR; Whitehead SS; Esteves-Jaramillo A; Shekar T; Lee JJ; Macey J; Kelner SG; Coller BG; Boulos FC; Nogueira ML
    N Engl J Med; 2024 Feb; 390(5):397-408. PubMed ID: 38294972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the dengue vaccine TAK-003 in an outbreak response: Modeling the Sri Lanka experience.
    Fernando L; Kastner R; Wickramasinghe P; Fernando AD; Gunasekera D; Nguyen VH; Liu M; LeFevre I; Wallace D; Folschweiller N; Biswal S
    PLoS Negl Trop Dis; 2024 Aug; 18(8):e0012376. PubMed ID: 39173075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: an observer-blind, randomised, phase 1 trial.
    Han HH; Diaz C; Acosta CJ; Liu M; Borkowski A
    Lancet Infect Dis; 2021 Sep; 21(9):1282-1292. PubMed ID: 34019802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years: a randomised, controlled, phase 2, non-inferiority study.
    Coronel-Martinez DL; Park J; López-Medina E; Capeding MR; Bonfanti AAC; Montalbán MC; Ramírez I; Gonzales MLA; Zambrano B; Dayan G; Chen Z; Wang H; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
    Lancet Infect Dis; 2022 Jun; 22(6):901-911. PubMed ID: 35364022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country.
    Tricou V; Eyre S; Ramjee M; Collini P; Mojares Z; Loeliger E; Mandaric S; Rauscher M; Brose M; Lefevre I; Folschweiller N; Wallace D
    Vaccine; 2023 Feb; 41(7):1398-1407. PubMed ID: 36681529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults.
    Gunale B; Farinola N; Yeolekar L; Shrivastava S; Girgis H; Poonawalla CS; Dhere RM; Arankalle V; Chandra Mishra A; Mehla R; Kulkarni PS
    Vaccine; 2023 Aug; 41(38):5614-5621. PubMed ID: 37532611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.